相关实验视频
Updated: Jun 10, 2025
08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
9.7K
甲胺介导的保护,防止多克索鲁比辛引起的心脏毒性
Ming-Li Sun1, Jun-Min Dong1, Chen Liu1
1Phase I Clinical Trial Research Center, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing 100038, China.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|October 15, 2024
概括
在细胞研究中,甲胺 (MET) 通过抑制氧化应激,显示出对多克索鲁比 (DOX) 诱导的心脏毒性的保护作用. 然而,由于药物不良反应,在大鼠模型中没有观察到这种保护作用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
背景情况:
- 之前的一项II期临床试验,研究甲双 (MET) 对于多克索鲁比 (DOX) 诱导的心脏毒性是不成功的.
- 多克索鲁比是一种广泛使用的化疗剂,已知会引起显著的心脏毒性.
- 了解保护机制和确定MET有效性的可靠指标对于未来的临床应用至关重要.
研究的目的:
- 确认MET对DOX诱导心脏毒性的保护作用,并使用H9C2细胞在体外阐明其机制.
- 建立一个用于DOX诱导心脏毒性的Wistar大鼠模型.
- 确定临床相关的指标,以评估MET的体内保护潜力,以指导未来的临床试验.
主要方法:
- 在体外:评估MET对H9C2细胞活力和细胞毒性的影响;使用二乙测量了线内反应性氧物种 (ROS).
- 在体内:在Wistar大鼠 (n=18) 中建立了DOX诱导的心脏毒性模型,分为对照组,DOX和DOX+MET组.
- 评估体重,药物不良反应 (ADRs),心肌损伤,心脏功能,氧化应激和心脏组织组织病理学.
主要成果:
- 在体外,MET证明了对H9C2细胞的DOX诱导心脏毒性的剂量依赖性保护,与ROS抑制一致.
- 成功建立了DOX诱导心脏毒性的体内大鼠模型.
- 在体内,MET没有显示出保护作用,这可能是由于吐等不良药物反应影响了能量摄入.
结论:
- 通过抑制氧化应激,MET介导的保护对DOX诱导的心脏毒性被证实在体外.
- 需要进一步研究MET在体内和临床环境中的最佳条件.
- 识别和减轻ADR对于DOX诱导心脏毒性的MET的成功临床转化至关重要.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
178
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
178
01:26Heart Failure Drugs: Inotropic Agents
534
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
534
01:46Electron Transport Chain: Complex I and II
12.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.1K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
01:22Heart Failure Drugs: Diuretics
346
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
346